Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia
Atherosclerosis, 06/04/2012SolanasBarca M et al. –
Rare APOE mutations are responsible for approximately 3.5% of familial combined hyperlipidemia (FCHL) cases in this population. APOE R136S and p.Leu149del induce autosomal dominant familial dysbetalipoproteinemia (FD) and a phenotype indistinguishable from FCHL, respectively.
In 279 unrelated subjects with FCHL in whom a functional LDLR mutation was excluded, sequencing of the entire APOE gene detected 9 carriers of a rare mutation: 5 subjects (1.8%) with the R136S mutation (arginine at residue 136 changed to serine) and 4 subjects (1.4%) with the p.Leu149del mutation, a 3–bp inframe deletion that results in the loss of leucine at position 149.
Both genetic defects were detected with similar frequency (2.5% and 1.3%, respectively) in an independent group of 160 FCHL subjects from other locations in Spain.
Family studies demonstrated cosegregation of these APOE mutations with hyperlipoproteinemia.
R136S carriers showed dysbetalipoproteinemia, while the lipid phenotype of p.Leu149del carriers was IIa or IIb.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.